Galpha Laboratories

What Galpha Laboratories does

Galpha Laboratories Limited is an Indian privately held pharmaceutical formulations manufacturer and marketer headquartered in Mumbai. The company operates through four business divisions: Galpha Pharma (domestic retail healthcare, supplied through 26 Depots/C&F agents and over 1,000 stockists across India with a catalogue spanning anti-allergic, anti-infective, anti-pyretic, anti-viral, dermatology, gastroenterology, nutritional, and pain management categories), Exports (international business via private markets, tenders, licensing, registration, and contract manufacturing), Ecogen (the fastest-growing division, focused on antibiotics and herbal preparations), and Institution (government institutional sales with a dedicated field force reaching 15,000+ medical professionals annually across India).

The company manufactures across three plants: Baddi Unit 1 (oral solids, pellets, oral liquids, soft gels), Baddi Unit 2 (nutraceutical liquids), and Ankleshwar (pellets and enema fill technology). Manufacturing is accredited by WHO CGMP, UK-MHRA, EU GMP, and ISO 9001:2008/ISO 14001:2004, supporting both domestic institutional tenders and regulated-market exports. The company employs 1,000+ staff in India and abroad and is family-controlled, with the Singh family occupying the Chairman/Managing Director and Director positions on the board.

The revenue model is anchored on unit-priced generic pharmaceutical sales across three channels: domestic retail distribution through stockists, government institutional sales via tender participation, and international export transactions. The 2025 MRP revision (notification no.9/2025) confirms ongoing regulatory pricing compliance for the domestic formulary. Revenue and financial performance are not publicly disclosed.

Name

Galpha Laboratories

Legal name

Galpha Laboratories Limited

Website

https://galpha.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Indian privately held pharmaceutical formulations manufacturer and marketer operating across domestic retail (1,000+ stockists), government institutional sales, and international exports, with three certified manufacturing plants in Baddi and Ankleshwar serving therapeutic categories from antibiotics to nutraceuticals.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG)

Keywords

• Pharmaceutical formulations
• Generic medicines
• Contract manufacturing
• Pharmaceutical exports
• Institutional pharma sales

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Formulations Sales: Manufacturing and marketing of pharmaceutical finished dosage forms including tablets, capsules, oral liquids, pellets, soft gels, and nutraceuticals across domestic and international markets
2. International Exports: Global pharmaceutical exports through private markets, tenders, licensing and registration, and contract manufacturing arrangements
3. Institutional Sales: Supply of generic pharmaceuticals to government institutions and healthcare facilities, with institutional marketing budget of approximately Rs. 55.5 billion

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Galpha Laboratories Limited manufactures and markets pharmaceutical finished dosage formulations including tablets, capsules, oral liquids, pellets, soft gels, and nutraceuticals across multiple therapeutic categories. The company sells through four divisions—Galpha Pharma (domestic retail), Exports (international), Ecogen (innovative healthcare solutions), and Institution (government/institutional)—using a network of 26 depots, 1,000+ stockists, and direct sales to government healthcare facilities in India and overseas.

Product overview

Galpha Laboratories is a pharmaceutical formulation manufacturing and marketing company with multiple divisions: Galpha Pharma (core pharmaceutical products), Exports (international business), Ecogen (healthcare solutions distribution), and Institution (government institutional sales). The Galpha Pharma division offers products across therapeutic categories including Anti-Allergic (LERZIN-M, BRETHESE), Anti-Infective (ODICEF family, CLANOXY, G-MERO, PIPTAZONE, GAL-LINI, GALOXIN OZ), Anti-Pyretic (GALMOL), Anti-Viral (ZICOV-KIT), Dermatology (IT GAL, LU-GAL), Gastroenterology (EZIVAC, ISV, PANDOSTAL, ENZ, GAL-COL, PAN-GAL), Nutritional (B-COLEN NS GRP, CIDRO, GALROL, ZASADA, GALCIUM), and Pain Management (RHUMACORT, RHUMACORT PLUS, RHUMACORT TH). Manufacturing operations span three facilities: Baddi Unit 1 (oral solids, pellets, liquids, soft gels), Baddi Unit 2 (nutraceuticals liquids), and Ankleshwar Plant (pellets, enema fill).

Differentiator

Problem solved

Functional benefit

Brands

• Galpha Pharma: Pharmaceutical division providing healthcare products through 26 Depots/C&F and over 1000 Stockists across India
• Galpha Exports
• Ecogen
• Galpha Institution

Products and services

• Anti-Allergic Pharmaceutical Products Anti-allergic formulations including LERZIN-M (Levoctrizine and Montelukast) and BRETHESE (Diphenhydramine Hydrochloride, Ammonium Chloride, Sodium Citrate, and Menthol) for retail and institutional customers.
• Anti-Infective Antibiotic Portfolio Broad anti-infective antibiotic range including ODICEF family (Ceftriaxone, Cefixime and combinations), CLANOXY (Amoxicillin and Clavulanic Acid), G-MERO (Meropenem), PIPTAZONE (Piperacillin and Tazobactum), GAL-LINI (Linezolid), GALOXIN OZ (Ofloxacin and Ornidazole), and MIK (Amikacin).
• Anti-Pyretic and Anti-Viral Products Anti-pyretic GALMOL (Paracetamol) and anti-viral combination ZICOV-KIT (Ivermectin, Doxycycline, and Zinc Acetate) for fever and viral infection management.
• Dermatology and Gastroenterology Products Dermatology antifungals IT GAL (Itraconazole) and LU-GAL (Luliconazole); gastroenterology products EZIVAC (Sodium Chloride and Glycerine), ISV (Ondansetron), PANDOSTAL (Pantaprazole and Domperidone), ENZ (Diastase and Pepsin), GAL-COL (Dill Oil, Fennel Oil, and Simethicone), and PAN-GAL (Pantaprazole).
• Nutritional Supplements Portfolio Multivitamin and multimineral nutritional supplements including B-COLEN NS GRP, CIDRO (Vitamin C, Vitamin D, and Zinc), GALROL (Vitamin D), ZASADA (Zinc Gluconate), and GALCIUM (Calcium and Vitamin D). The B-Colen NS Range holds position 4 in India's multi-vitamin/multi-mineral market.
• Pain Management Range Pain management formulations including RHUMACORT (Diclofenac and Paracetamol), RHUMACORT PLUS (Aceclofenac and Paracetamol), and RHUMACORT TH (Diclofenac and Thiocolchicoside).
• Galpha Pharma Distribution Division Primary pharmaceutical division providing healthcare products through 26 Depots/C&F and over 1,000 stockists across India, covering anti-allergic, anti-infective, anti-pyretic, anti-viral, dermatology, gastroenterology, gynecologist, nutritional, and pain management categories.
• Pharmaceutical Exports Division International business division operating through private markets, tenders, licensing and registration, contract manufacturing, and various distribution models for global pharmaceutical exports.
• Ecogen Healthcare Solutions Division Fastest-growing division specializing in antibiotics and herbal preparations with strong distribution network across India, extending Galpha's reach to medical fraternity and ailing masses with innovative healthcare solutions.
• Institution Division (Government Institutional Sales) Institutional marketing division covering therapeutic segments including antibiotics, antipeptic ulcerants, NSAIDS, muscle relaxants, hematinics, and multivitamins, with Rs. 55.5 billion institutional marketing budget. Engages 15,000+ medical professionals annually and supplies generic pharmaceuticals to government hospitals and healthcare facilities.
• Baddi Unit 1 Manufacturing Facility Large-scale manufacturing facility with General Oral Solid Dosages (tablets and capsules), Pellets manufacturing, Oral liquid manufacturing, and Soft Gel production lines. Accredited with WHO CGMP, UK-MHRA, ISO 9001:2008, and ISO 14001:2004; received EU GMP approval.
• Baddi Unit 2 Manufacturing Facility Highly specialized liquid-line manufacturing plant dedicated to nutraceuticals production, complementing Unit 1's broader formulation capabilities.
• Ankleshwar Plant Manufacturing Facility Specialized manufacturing unit focusing on pellet manufacturing and enema fill technology. ISO 9001:2008 certified; serves as the company's regional hub in Gujarat.

Quantifiable outcome

• B-Colen NS Range moved to position 4 in multi-vitamin/multi-mineral market with highest growth among top 5 brands
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Multinational Pharmaceutical CompaniesminorStrategic or Co-development PartnerVarious multinational pharmaceutical companies participate in tenders with Galpha's institutional marketing division, helping strengthen institutional marketing and boost market share. This collaboration enables Galpha to serve as an attractive partner for international companies seeking to participate in government healthcare tenders.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/galphalaborato1
• Facebookfacebook.com/galphaLabs
• LinkedInlinkedin.com/company/galpha-laboratories-limited-mumbai

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galpha Laboratories